EGFR and non-small cell lung carcinoma: The presence of EGFR activating mutations is an established predictive biomarker in non-small cell lung cancer (NSCLC) with in-frame deletions of exon 19 (E746_A750) and L858R substitution in exon 21 accounting for > 90% of all activating mutations [17].